Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCQ | Q04759 | 1/20 | 0.32 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.32 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.31 |
| ▸ | IDH2 | P48735 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
| ▸ | BTK | Q06187 | 2/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | JAK3 | P52333 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19670500 | 0.88 | MAP4K4 (0.43) | PDE10ADGAT2MAP4K4BTK | |
| SCHEMBL19670351 | 0.88 | MAP4K4 (0.43) | PDE10ADGAT2MAP4K4BTK | |
| SCHEMBL16754552 | 0.82 | TRPV1 (0.40) | PIK3C3DGAT2BTKLCKJAK2 | |
| SCHEMBL16754313 | 0.82 | TRPV1 (0.40) | PIK3C3DGAT2BTKLCKJAK2 | |
| SCHEMBL16754311 | 0.82 | TRPV1 (0.40) | PIK3C3DGAT2BTKLCKJAK2 | |
| SCHEMBL19670506 | 0.80 | MAP4K4 (0.46) | PDE10AMAP4K4IDH2 | |
| SCHEMBL19670672 | 0.80 | MAP4K4 (0.46) | PDE10AMAP4K4IDH2 | |
| SCHEMBL16754512 | 0.79 | TRPV1 (0.40) | PIK3C3DGAT2LCKJAK2NTRK1 | |
| SCHEMBL16754324 | 0.79 | TRPV1 (0.40) | PIK3C3DGAT2LCKJAK2NTRK1 | |
| SCHEMBL16754516 | 0.79 | TRPV1 (0.40) | PIK3C3DGAT2LCKJAK2NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-02-14 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PRKCQ 1416/4885GRM4 4326/4885PIK3C3 4778/4885 |
| US-20190048016-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PRKCQ 1738/4885GRM4 4593/4885PIK3C3 4718/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | PRKCQ 1416/4885GRM4 4326/4885PIK3C3 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.